Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director | June 30, 2023 | July 03, 2023 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Accounting Officer | July 28, 2026 | July 31, 2026 |
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date June 30, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,602 |
Reported balance
After 2023-06-30 transaction · row 1
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 21,219 · Balance 40,602 F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-06-30 | Direct | 42,438 |
Reported balance
After 2023-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-30 · Grant · Acquired 42,438 · Balance 42,438 F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024.
F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 10,000 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 15,000 · Balance 25,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 15,000 · Balance 10,000 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 31, 2026 00:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003416 · form4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3 · derivative.exercise_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting. F3 · derivative.expiration_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerOrdinary Shares, par value $0.01 per share | 15,000 | $8.56 | $128,400.00 |
DisclosureSEC source: 0000905148-26-003416 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003416 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:51 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0000905148-26-001181 · form4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2036-03-03 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:52 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantOrdinary Shares, par value $0.01 per share | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002661 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0000905148-25-000889 · form4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Ordinary Shares · 70,000 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 02:09 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $30.30 | $0.00 |
DisclosureSEC source: 0000905148-24-000840 · form4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Ordinary Shares · 54,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 00:01 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000905148-24-000282 · form4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 5,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 00:01 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,000 | $34.00 | $170,000.00 |
DisclosureSEC source: 0000905148-24-000282 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 00:01 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $13.53 | $67,650.00 |
DisclosureSEC source: 0000905148-24-000282 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 00:17 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000905148-23-001682 · form4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 5,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 00:17 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,322 | $37.45 | $124,408.57 |
DisclosureSEC source: 0000905148-23-001682 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $37.14 to $37.82, inclusive. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 00:17 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,678 | $36.68 | $61,543.17 |
DisclosureSEC source: 0000905148-23-001682 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,322 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $36.095 to $37.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 00:17 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $13.53 | $67,650.00 |
DisclosureSEC source: 0000905148-23-001682 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2023 Filed Nov 30, 2023 23:24 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000905148-23-001531 · form4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 5,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| November 30, 2023 Filed Nov 30, 2023 23:24 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,000 | $34.00 | $170,000.00 |
DisclosureSEC source: 0000905148-23-001531 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| November 30, 2023 Filed Nov 30, 2023 23:24 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $13.53 | $67,650.00 |
DisclosureSEC source: 0000905148-23-001531 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 00:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000905148-23-001201 · form4.xml · derivative · entry 5 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 5,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 00:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 294 | $42.28 | $12,430.11 |
DisclosureSEC source: 0000905148-23-001201 · form4.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $42.17 to $42.38, inclusive. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 00:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,917 | $41.38 | $120,718.00 |
DisclosureSEC source: 0000905148-23-001201 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 294 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $40.90 to $41.88, inclusive. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 00:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,789 | $40.27 | $72,043.21 |
DisclosureSEC source: 0000905148-23-001201 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,211 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $39.85 to $40.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| October 25, 2023 Filed Oct 26, 2023 00:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $13.53 | $67,650.00 |
DisclosureSEC source: 0000905148-23-001201 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 21:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000905148-23-000946 · form4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 21:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,000 | $52.36 | $261,807.00 |
DisclosureSEC source: 0000905148-23-000946 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: This transaction was executed in multiple trades in prices ranging from $52.01 to $52.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 21:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0000905148-23-000946 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2023 Filed Aug 19, 2023 00:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000905148-23-000772 · form4.xml · derivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| August 18, 2023 Filed Aug 19, 2023 00:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,000 | $57.18 | $285,922.50 |
DisclosureSEC source: 0000905148-23-000772 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $56.95 to $57.67, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. Read SEC document |
| August 18, 2023 Filed Aug 19, 2023 00:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0000905148-23-000772 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 00:50 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001140361-23-035280 · form4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 00:50 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,034 | $70.08 | $72,459.00 |
DisclosureSEC source: 0001140361-23-035280 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F3 · price: The transaction was executed in multiple trades in prices ranging from $69.95 to $70.17, inclusive. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 00:50 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,966 | $68.96 | $273,484.26 |
DisclosureSEC source: 0001140361-23-035280 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,034 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $68.635 to $69.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 00:50 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001140361-23-035280 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077655 · tm2320411-4_4seq1.xml · derivative · entry 2 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077655 · tm2320411-4_4seq1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,602 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · derivative · entry 5 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 529 | $69.99 | $37,026.88 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F4 · price: The transaction was executed in multiple trades in prices ranging from $69.91 to $70.20, inclusive. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,471 | $69.49 | $171,698.92 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F3 · price: The transaction was executed in multiple trades in prices ranging from $68.90 to $69.85, inclusive. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,000 | $67.88 | $135,768.40 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $67.41 to $68.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001140361-23-030563 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001140361-23-025833 · form4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| May 19, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,177 | $74.47 | $162,128.16 |
DisclosureSEC source: 0001140361-23-025833 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F3 · price: The transaction was executed in multiple trades in prices ranging from $74.175 to $74.98, inclusive. Read SEC document |
| May 19, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,823 | $73.63 | $207,850.15 |
DisclosureSEC source: 0001140361-23-025833 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,177 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $73.09 to $74.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| May 19, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001140361-23-025833 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2023 Filed Apr 22, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001140361-23-019684 · form4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| April 19, 2023 Filed Apr 22, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,083 | $53.25 | $110,917.04 |
DisclosureSEC source: 0001140361-23-019684 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F3 · price: The transaction was executed in multiple trades in prices ranging from $53.165 to $53.35, inclusive. Read SEC document |
| April 19, 2023 Filed Apr 22, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,917 | $52.64 | $153,562.84 |
DisclosureSEC source: 0001140361-23-019684 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,083 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022. F2 · price: The transaction was executed in multiple trades in prices ranging from $52.14 to $53.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| April 19, 2023 Filed Apr 22, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001140361-23-019684 · form4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001140361-23-013190 · form4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,481 Underlying: Ordinary Shares · 5,000 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. F5 · balance_after: The Reporting Person's prior Form 4 filed on March 17, 2023 inadvertently transposed the first two digits of the number of options reported in Column 9, reporting 53,481 options beneficially owned following the Reporting Person's transaction in these options on March 15, 2023, instead of the correct number of 35,481 options beneficially owned. The correct number of 35,481 options beneficially owned was used for purposes of calculating the number of options reported in Column 9 of this Form 4. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,097 | $48.47 | $53,166.43 |
DisclosureSEC source: 0001140361-23-013190 · form4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $48.33 to $48.73, inclusive. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,903 | $47.51 | $185,443.24 |
DisclosureSEC source: 0001140361-23-013190 · form4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,097 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $47.305 to $48.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.